Anzeige
Mehr »
Login
Samstag, 18.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P9SM | ISIN: CA28500L1094 | Ticker-Symbol:
Branche
Rohstoffe
Aktienmarkt
Sonstige
1-Jahres-Chart
ELECTRIC ROYALTIES LTD Chart 1 Jahr
5-Tage-Chart
ELECTRIC ROYALTIES LTD 5-Tage-Chart
ACCESS Newswire
366 Leser
Artikel bewerten:
(2)

Gleason & Sons LLC: After Electric Royalties' Portfolio Rockets to 72 Assets, Stefan Gleason Further Boosts Equity Stake

Finanznachrichten News

CHARLOTTE, NC / ACCESSWIRE / May 30, 2024 / Stefan Gleason (the "Acquiror" or "Gleason") today announced that he is filing another early warning report in connection with his acquisition of additional shares of Electric Royalties Ltd. (TSXV:ELEC)(OTCQB:ELECF) ("Electric Royalties" or the "Company").

After acquiring 2,000,000 Electric Royalties shares today via a private, off-market transaction, Gleason now beneficially owns or has control or direction over more than 26% of the Company's issued and outstanding common shares.

"With Electric Royalties recently having more than tripled its overall holdings to 72 assets (including 40 royalties), I am pleased to continue the process of bolstering my long-term position in the Company by accumulating shares via open market purchases as well as private transactions," said Gleason.

"Meanwhile, with positive developments recently announced in connection with many of the Company's royalties - including Battery Hill, Seymour Lake, Mont Sorcier, Graphmada, Graphite Bull, Zonia, Kenbridge, Authier, and Chubb - as well as using a conservative NPV analysis of the Company's anticipated future cash flows, I believe Electric Royalties shares remain remarkably undervalued."

In order to make further share acquisitions above the 20% threshold, Gleason has been utilizing both the "Normal Course Purchase Exemption" and the "Private Agreement Exemption" in National Instrument 62-104 - Take-Over Bids and Issuer Bids.

Stefan Gleason is a Charlotte-based entrepreneur who leads several privately held businesses in the United States, including Money Metals Exchange LLC. Money Metals is one of the largest precious metals dealers and depositories in North America.

Gleason is also a Director of Electric Royalties. His family office, Gleason & Sons LLC, recently provided Electric Royalties an expanded C$10 million convertible credit facility that potentially enables the Company to acquire new assets without raising equity until such time as its shares are fairly valued, thereby limiting dilution of existing shareholders.

On May 30, 2024, Acquiror closed on a private agreement to acquire 2,000,000 (at a cost of C$400,000, or $0.20 per share). Prior to May 30, the Acquiror held an aggregate of 23,746,404 Common Shares, representing 24.02% of the issued and outstanding Shares on an as converted and partially diluted basis. After the acquisition on May 30, the Acquiror held 25,746,404 Common Shares, or 26.05% of the issued and outstanding Shares on an as converted and partially diluted basis.

On April 30, 2024, the Acquiror previously filed a report under the early warning reporting rules of Canadian securities laws, disclosing that he beneficially owned or had control or direction over 23,199,004 Common Shares, at the time representing 24.015% of the Company's issued and outstanding Shares on an as converted and partially diluted basis. The Acquiror is filing this latest early warning report because he has now accumulated more than 2% of the Company's issued and outstanding Shares since his prior filing on April 30, 2024.

This early warning news release is issued under the early warning provisions of Canadian securities legislation, including National Instrument 62-104 - Take-Over Bids and Issuer Bids and National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues. A copy of the Early Warning Report will be filed at www.sedar.com.

For further information, contact:

Stefan Gleason
Gleason & Sons LLC
15720 Brixham Hill Avenue, #205
Charlotte, NC 28277
Tel: 208-577-2230

This release includes certain statements that may be deemed "forward-looking statements." All statements in this release, other than statements of historical facts, that address anticipated future events are forward-looking statements. Although the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future events and actual results or developments may differ materially from those in the forward-looking statements including as a result of the failure to obtain regulatory approvals, the availability of royalties, the production of properties underlying royalties not being as anticipated, and the Company's cash flow position deteriorating as a result of business or economic conditions.

SOURCE: Gleason & Sons LLC



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.